Meta-Analysis of SGLT Inhibitors for Kidney Disease Prevention in Type 2 Diabetes

Seven studies comprising 15,228 participants receiving SGLT inhibitors and 12,736 receiving placebo were analyzed in this systematic review. The meta-analysis, conducted by Zhenlin Zhang and published on figshare in 2026, found a 53% reduction in chronic kidney disease composite outcomes. The review included literature from MEDLINE, Embase, and Cochrane databases up to January 1, 2025.

Use Cases

• Validate the primary preventive effect of SGLT inhibitors based on the reported hazard ratio (RR 0.47).
• Assess heterogeneity in clinical trial outcomes using the reported I² statistic of 6%.
• Compare intervention efficacy between randomized controlled trials and observational studies as described in the results.

Strengths

• Analysis includes data from 15,228 participants receiving the intervention and 12,736 receiving placebo.
• Results show a statistically significant effect (P < 0.0001) with low heterogeneity (I² = 6%).
• Systematic review protocol is registered with PROSPERO (CRD420251168634).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a 30.4 KB DOCX file, indicating a very small scale likely containing summary tables rather than raw patient data.

Provenance

Source

Literature from MEDLINE, Embase, and Cochrane databases.

Collection Method

Systematic review and meta-analysis of randomized controlled trials and observational studies.

Time Range

Literature search up to January 1, 2025.

Freshness

Last updated 2026-03-18 07:38:48; freshness should be verified.

Geography

null